Cargando…

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury

BACKGROUND: Recently, glucagon-like peptide-1 (GLP-1)-based therapy, including dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, has emerged as one of the most popular anti-diabetic therapies. Furthermore, GLP-1-based therapy has attracted increased attention not only for its gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terawaki, Yuichi, Nomiyama, Takashi, Kawanami, Takako, Hamaguchi, Yuriko, Takahashi, Hiroyuki, Tanaka, Tomoko, Murase, Kunitaka, Nagaishi, Ryoko, Tanabe, Makito, Yanase, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240860/ https://www.ncbi.nlm.nih.gov/pubmed/25407968 http://dx.doi.org/10.1186/s12933-014-0154-3

Ejemplares similares

Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
por: Terawaki, Yuichi, et al.
Publicado: (2015)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
por: Tsutsumi, Yoko, et al.
Publicado: (2015)

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet
por: Horikawa, Tsuyoshi, et al.
Publicado: (2020)

Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database
por: Tanabe, Makito, et al.
Publicado: (2015)

Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database
por: Tanabe, Makito, et al.
Publicado: (2016)

Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression
por: Shigeoka, Toru, et al.
Publicado: (2020)

Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line
por: Fukuda, Takashi, et al.
Publicado: (2016)

Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives
por: Yanase, Tashihiko, et al.
Publicado: (2017)

Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes
por: Muta, Yoshimi, et al.
Publicado: (2019)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
por: Nakaoku, Yuriko, et al.
Publicado: (2019)

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2012)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis
por: Terawaki, Yuichi, et al.
Publicado: (2013)

SUN-026 Selective Androgen Receptor Modulator S42 Has Anabolic and Anti-Catabolic Effects on Cultured Myotubes
por: Muta, Yoshimi, et al.
Publicado: (2019)

Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis
por: Shiheido-Watanabe, Yuka, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
por: Manrique, Camila, et al.
Publicado: (2016)

Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, Reduces Physical and Behavioral Effects of Morphine Withdrawal
por: Listos, Joanna, et al.
Publicado: (2022)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
por: Wang, Shen-Chih, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
por: Darsalia, Vladimer, et al.
Publicado: (2019)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
por: Cooper, Mark E., et al.
Publicado: (2019)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation
por: Ide, Makoto, et al.
Publicado: (2020)

Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors
por: Patorno, Elisabetta, et al.
Publicado: (2017)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans
por: Batchu, Sri Nagarjun, et al.
Publicado: (2020)

A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein
por: Schnapp, Gisela, et al.
Publicado: (2020)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose
por: Salheen, Salheen M., et al.
Publicado: (2015)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
por: Kitagawa, Noriyuki, et al.
Publicado: (2018)

Significance of Metformin Use in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
por: Aroor, Annayya R., et al.
Publicado: (2017)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5t7dmvat1sucq6ktnm3rskn6la